Two decades of glycan science
GlycoNex's work is grounded in the GlycoSH antibody bank, a collection of anti-glycan monoclonal antibodies built over more than twenty years of glycobiology research.
Careers
Join the team behind glycan-directed oncology
GlycoNex (TWO:4168) is a clinical-stage biotechnology company founded in 2001, developing glycan-targeted antibody-drug conjugates and biosimilars from its facility in New Taipei City, Taiwan. Following Japan PMDA clearance of its lead ADC GNX1021 for Phase 1 in April 2026, the company is advancing a pipeline that spans antibody discovery through GMP manufacturing and clinical operations — and is growing the team behind it.
Founded
2001
Listing
TWO:4168
Location
Xizhi, New Taipei City
Internships
Since 2016
01 — Why GlycoNex
Why GlycoNex
Clinical-stage momentum
Lead ADC GNX1021 was cleared by Japan's PMDA for first-in-human Phase 1 in April 2026, with programs advancing across ADC, pro-antibody, and biosimilar modalities.
The full value chain, in one place
Antibody discovery, process development, 200-litre GMP production, and clinical operations all sit within a single integrated organization.
International collaboration
GlycoNex co-develops with partners including Mitsubishi Gas Chemical and Nippon Kayaku, on programs intended for global markets.
02 — Where you'd fit
Where you'd fit
GlycoNex is a fully integrated R&D-to-manufacturing organization, spanning antibody discovery, process development, GMP production, clinical operations, quality management, and business development. Roles range across laboratory research, analytical and manufacturing science, clinical and regulatory affairs, and corporate functions. Current openings — with specific responsibilities and requirements — are listed on our 104 corporate page.
03 — Students and early careers
Students and early careers
Since 2016, GlycoNex has provided internship and course-based training opportunities in partnership with universities, giving students hands-on experience across antibody discovery and development.